Skip to main content
. 2023 Aug 18;14:1229724. doi: 10.3389/fimmu.2023.1229724

Table 1.

Patterns of serum antibodies following pediatric GII.17 infections.

Subject ID ORF1/2 sequencing from stool Post-infection serum antibodies1
Binding Blockade
Specificity EC50 titer2 Specificity IC50 titer3
62 II I,II, IIIb 287,210,150 I 979
132 II I,II, IIIb 481,389,406 I 479
317 II I,II, IIIb 235,192,113 I 460
208 IIIb I,II, IIIb 350,281,554 IIIb 625
263 IIIb I,II, IIIb 292,518,1252 IIIb 2974
369 IIIb I,II, IIIb 563,332,1502 I, IIIb 406, 7290
434 IIIb I,II, IIIb 333,357,366 I, IIIb 500, 1843

1Sera were collected at different times post infection which limits direct comparisons between subjects and may impact the relative titer between clusters as other infections may have occurred prior to GII.17 infection and between the symptomatic GII.17 infection and follow up sera collections.

2Binding titers with respect to indicated specificities. Value indicated is reciprocal of the serum dilution at half maximum binding (50% effective concentration, EC50) for EIA. Assay cutoff is EC50 < 50.

3Blockade titers with respect to indicated specificities. Value indicated is reciprocal of the serum dilution at half maximum blockade activity (50% inhibitory concentration, IC50). Assay cutoff is IC50 < 20.